Bond Pet Foods makes pet food from real animal protein, without the animal by working with biotechnology. Bond Pet Foods develops meat proteins obtained from animal cells (no slaughter required) and natural microbes. It is fed a nutrient-rich broth of vitamins, sugars, and minerals in fermentation tanks, without the pharmaceuticals. Bond Pet Foods was founded on 2015 and is headquartered in Boulder, Colorado.
Codetta Bio is a life sciences company working on a novel multi-omic analysis platform based on digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsIPCR) (dsiPCR). Its integrated reagent, hardware, and software platform enable multiplexed, multi-omic liquid biopsy and isolated DNA, RNA, and protein analyses. The company aims to provide the life sciences community with a simultaneous multi-omic dsPCR solution that will accelerate research and development of next-generation therapies, improving patient care and quality of life.
Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection.
Meiogenix is a biotech company developing breeding technologies to unlock the unexplored genetic diversity of organisms. Meiogenix expands the natural biodiversity and helps to develop new products to address global food and industrial challenges.
SimBioSys is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.
InterVenn is a life science company unlocking the value of glycoproteomics—glycosylated proteins which are responsible for driving protein function—for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to improve patient outcomes significantly. Still, it has remained inaccessible due to its vast complexity. InterVenn has pioneered a first-of-its-kind AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history. The company’s platform can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics. Its proprietary technology platform is accessible to pharma partners seeking rich biology insights to propel their research and development efforts. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert & serial entrepreneur Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.
Stemson Therapeutics is driven by a vision where anyone battling the emotional trauma or social stigma of hair loss has an opportunity to truly cure their condition and safely restore their natural hair. Our engineered cells are combined with a unique tissue engineering solution and are capable of generating a net new supply of hair follicles for patients in need. Stemson
BloodQ develops an analytical platform designed for cancer drug treatment. Its platform captures disease molecular signals in circulating DNA to improve sensitivity, specificity, and timing in diagnostic and disease management, thereby providing patients personalized cancer treatment.
Attune Neurosciences helps improve human health and performance by creating clinically proven, non-invasive neurostimulation products. It is a medical device company. The company is initially targeting sleep- and wake-related conditions to support patients, the government, and industrial applications.
BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems.
InterVenn is a life science company unlocking the value of glycoproteomics—glycosylated proteins which are responsible for driving protein function—for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to improve patient outcomes significantly. Still, it has remained inaccessible due to its vast complexity. InterVenn has pioneered a first-of-its-kind AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history. The company’s platform can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics. Its proprietary technology platform is accessible to pharma partners seeking rich biology insights to propel their research and development efforts. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert & serial entrepreneur Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.
Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health.
At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques.
Intabio is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio was founded in 2015 by Erik Gentalen and Lena Wu and is based in Fremont, California, United States.
InterVenn is a life science company unlocking the value of glycoproteomics—glycosylated proteins which are responsible for driving protein function—for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to improve patient outcomes significantly. Still, it has remained inaccessible due to its vast complexity. InterVenn has pioneered a first-of-its-kind AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history. The company’s platform can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics. Its proprietary technology platform is accessible to pharma partners seeking rich biology insights to propel their research and development efforts. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert & serial entrepreneur Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.
Intabio is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio was founded in 2015 by Erik Gentalen and Lena Wu and is based in Fremont, California, United States.
Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health.
NanoCellect Biomedical develops and delivers microfluidic-based solutions that are affordable, compact, and easy to use. Its expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.
Intabio is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio was founded in 2015 by Erik Gentalen and Lena Wu and is based in Fremont, California, United States.
Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.
Acquired 2020. Synthomics' distributed synthesis model places the power of DNA and RNA synthesis directly in the hands of the end-user. Leveraging multiple innovations in instrumentation and consumables, the technology empowers laboratories to fuel more rapid innovation in biological discovery.
Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling the development of therapeutics for agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
Pivot Bio is improving and using a deep understanding of the microbiome to advance crop nutrition. They believe that microbes can deliver nutrients, protect against pests, and improve crop quality better than chemical fertilizers and pesticides. They leverage engineering principles and data science to map the dynamics of the plant microbiome and evolve beneficial traits. Their team thrives on collaboration and communication as they seek to create revolutionary fertilizers that transform food supply and improves the planet. Pivot Bio's proprietary ON Technology harnesses the power of naturally occurring microbes to provide more nutrients to crops. It’s a smart, sustainable way for farmers to improve yield as they work to help feed the world’s growing population. Their current efforts are focused on enabling microbes to fix and supply more nitrogen to corn. Pivot Bio was founded in 2010 and is headquartered in Berkeley, California, United States.
Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health.
Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.
Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling the development of therapeutics for agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
Zephyrus Biosciences provides research tools to enable protein analysis at the single-cell level. Addressing the burgeoning single-cell analysis market, our first product, the scWestern system, enables western blotting on individual cells for the first time. Researchers will utilize Zephyrus’s products to gain new insights into the biology of cancer, stem cells, neurology, and human disease and development. It was founded in 2013 and headquartered in Berkeley, California.
Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.